Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.
Informed Consent: An informed consent form, signed and dated, must be provided before any steps in the study are performed.
Age: Males or females aged 18 to 75 years.
Diagnosis: Histologically or cytologically confirmed small cell lung cancer (SCLC).
Stage: Stage I-III (AJCC/UICC 8th edition TNM staging), where all lesions can be included in a single radical radiotherapy plan (i.e., limited-stage disease). Stage I-II must be inoperable.
Participation in Another Clinical Trial: Simultaneous participation in another clinical trial, unless it is an observational (non-interventional) study.
Mixed Histology: Histological subtype of mixed small cell and non-small cell lung cancer (SCLC).
Extensive-Stage SCLC: Diagnosis of extensive-stage SCLC.
Malignant Effusions: Pathologically confirmed malignant pleural effusion or pericardial effusion.